Related Experiment Video
Updated: Feb 3, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
Nannan Wang1, Linlin Wang2, Xiangjiao Meng2
1Department of Oncology, School of Medicine and Life Sciences, University of Jinan‑Shandong Academy of Medical Sciences, Jinan, Shandong 250022, P.R. China.
Abstract:
Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR‑sensitizing mutations or the T790M mutation. However, the potential therapeutic effect of osimertinib combined with ionizing irradiation (IR) is not well understood. The present study investigated treatment with osimertinib combined with IR in EGFR T790M non‑small cell lung cancer (NCI‑H1975) in vitro and in vivo. The results revealed that osimertinib inhibited proliferation and clonogenic survival following irradiation, decreased G2/M phase arrest in irradiated cells, and delayed DNA damage repair in a concentration‑ and time‑dependent manner. Furthermore, osimertinib alone or in combination with IR, blocked the phosphorylation of EGFR (Tyr1068/Tyr1173), protein kinase B and extracellular signal‑regulated kinase. Osimertinib also enhanced the antitumor activity of IR in tumor‑bearing nude mice. The results of the present study indicated that osimertinib has therapeutic potential as a radiation‑sensitizer in lung cancer cells harboring the EGFR T790M mutation, providing a rationale for clinically combining osimertinib with irradiation in EGFR T790M non‑small cell lung cancer.
Insights
Osimertinib enhances radiation therapy for EGFR T790M non-small cell lung cancer. This combination therapy inhibits cancer cell growth, DNA repair, and improves antitumor effects, showing promise for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Osimertinib is a third-generation EGFR tyrosine kinase inhibitor effective for EGFR-mutated lung cancers.
- The combination of osimertinib with ionizing radiation (IR) for EGFR T790M non-small cell lung cancer (NSCLC) lacks comprehensive understanding.
Purpose of the Study:
- To investigate the therapeutic effects of combining osimertinib with IR in EGFR T790M NSCLC.
- To evaluate the impact of this combination on cancer cell proliferation, DNA damage repair, and signaling pathways.
Main Methods:
- In vitro studies using NCI-H1975 lung cancer cells (EGFR T790M positive).
- In vivo studies using tumor-bearing nude mice models.
- Assays included proliferation, clonogenic survival, cell cycle analysis, DNA damage assessment, and Western blotting for signaling proteins.
Main Results:
- Osimertinib inhibited proliferation and clonogenic survival post-irradiation.
- Osimertinib delayed DNA damage repair and reduced G2/M phase arrest in irradiated cells.
- The combination therapy blocked EGFR and downstream signaling pathways (AKT, ERK) and enhanced antitumor activity in vivo.
Conclusions:
- Osimertinib acts as a potent radiation-sensitizer in EGFR T790M mutated NSCLC.
- This study provides a strong rationale for the clinical combination of osimertinib and IR in this patient population.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:02Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018
Related Concept Videos
Increasing Function
Lung Capacity
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Cancer Cell Migration through Invadopodia
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...